Abstract
The tailless homologue receptor (TLX) is a ligand-activated transcription factor acting as master regulator of neural stem cell homeostasis. Despite its promising potential in neurodegenerative disease treatment, TLX ligands are rare but required to explore phenotypic effects of TLX modulation and for target validation. We have systematically studied and optimized a TLX agonist scaffold obtained by fragment fusion. Structural modification enabled the development of two TLX agonists endowed with nanomolar potency and binding affinity. Both exhibited favorable chemical tool characteristics including high selectivity and low toxicity. Most notably, the TLX agonists comprise different scaffolds and display high chemical diversity enabling a use as set for target identification and validation studies.
Supplementary materials
Title
Supporting Information
Description
Contains Supplementary Figures and Tables as well as experimental procedures and analytical data.
Actions